Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.

被引：0

作者：

Massard, Christophe

Retz, Margitta

Hammerer, Peter

Quevedo, Fernando

Fong, Peter C. C.

Berry, William R.

Gurney, Howard

Piulats, Josep M.

Joshua, Anthony M.

Linch, Mark David

Kolinsky, Michael Paul

Romano, Emanuela

Sridhar, Srikala S.

Conter, Henry Jacob

Augustin, Marinela

Wu, Helen

Schloss, Charles

Poehlein, Christian Heinrich

Yu, Evan Y.

机构：

[1] Gustave Roussy Canc Campus, Villejuif, France

[2] Univ Paris Sud, Villejuif, France

[3] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany

[4] Acad Hosp Braunschweig, Braunschweig, Germany

[5] Mayo Clin, Rochester, MN USA

[6] Auckland City Hosp, Auckland, New Zealand

[7] Duke Univ, Sch Med, Cary, NC USA

[8] Macquarie Univ Hosp, Sydney, NSW, Australia

[9] Catalan Canc Inst, Barcelona, Spain

[10] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[11] UCL, Inst Canc, London, England

[12] Cross Canc Inst, Edmonton, AB, Canada

[13] Inst Curie, Paris, France

[14] Princess Margaret Canc Ctr, Toronto, ON, Canada

[15] Univ Western Ontario, Brampton, ON, Canada

[16] Klinikum Nurnberg, Nurnberg, Germany

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.5029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5029

引用

页数：2